Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
ESMERON (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
ESMERON
Date registered
Evaluation commenced
Decision date
Approval time
130 working days (255)
Active ingredients
rocuronium bromide
Registration type
EOI
Indication
ESMERON (solution for injection) is now also indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in paediatric patients from term newborn infants to adolescents.